Article
Environmental Sciences
Zhengyuan Chen, Yuhuan Wu, Bixia Wang, Jiamin Fang, Changlian Gan, Chuanlan Sang, Zhu Dun, Tajie Luosang, Qing Wang, Dawa Zeren, Tianqin Xiong
Summary: Clinical studies have shown a close relationship between intrahepatic cholestasis and intestinal injury, suggesting a disruption in the gut-liver axis. Treatment with Transmetil alleviated liver and gut injuries caused by intrahepatic cholestasis, indicating the importance of bile acids in linking the intestine and liver.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
(2021)
Article
Cell Biology
Peijie Wu, Ling Qiao, Han Yu, Hui Ming, Chao Liu, Wenjun Wu, Baixue Li
Summary: The study demonstrates that arbutin has a protective effect on cholestatic liver injury induced by ANIT by upregulating FXR and downstream enzymes associated with bile acid homeostasis. Furthermore, the findings suggest that arbutin may be a potential chemical molecule for cholestatic diseases by partly acting through the FXR pathway.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Plant Sciences
Jiannan Qiu, Jingyu Yan, Wei Liu, Xinzhu Liu, Jingchao Lin, Zeng Du, Li Qi, Jia Liu, Guoxiang Xie, Ping Liu, Xiaoning Wang
Summary: The study investigated the therapeutic effect of Huangqi decoction (HQD) and astragalosides on alpha-naphthylisothiocyanate (ANIT)-induced cholestasis in rats. The results showed that HQD and astragalosides treatment could alleviate the perturbation of bile acids and free fatty acids, improve liver function, and mitigate liver histopathological damage caused by ANIT.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Chang Wang, Fei Peng, Bohua Zhong, Ying Shi, Xiaomei Wang, Xueyuan Jin, Junqi Niu
Summary: The study showed that MBT1805 has therapeutic effects on ANIT-induced cholestasis, improving abnormal biochemical indicators, gallbladder enlargement, and histopathological changes. By regulating bile acid synthesis, biotransformation, and transport, MBT1805 helps relieve cholestasis.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, Research & Experimental
Soraya Salas-Silva, Jocelyn Lopez-Ramirez, Jonatan Barrera-Chimal, Roberto Lazzarini-Lechuga, Arturo Simoni-Nieves, Veronica Souza, Roxana U. Miranda-Labra, Felipe Masso, Marcelo G. Roma, Maria Concepcion Gutierrez-Ruiz, Leticia E. Bucio-Ortiz, Luis Gomez-Quiroz
Summary: This study demonstrates that HGF protects the kidney from damage caused by ANIT-induced cholestasis through its antioxidant properties. It reverses renal damage, decreases tubular cast formation, and controls renal oxidative stress.
Article
Pharmacology & Pharmacy
Miao Yan, Lin Guo, Yan Yang, Bikui Zhang, Zhenyan Hou, Yue Gao, Hongmei Gu, Hui Gong
Summary: Glycyrrhetinic acid alleviates ANIT-induced liver injury by regulating bile acid transporters, inflammation, and apoptosis, suggesting its potential as a therapeutic agent for cholestasis.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Toxicology
Xue Han, Chuyi Lin, Huijie Liu, Shan Li, Bei Hu, Lei Zhang
Summary: In this research, the protective effects and underlying mechanisms of allocholic acid (ACA) against cholestasis were investigated. ACA treatment effectively reduced serum indicators and ameliorated pathological injury caused by cholestasis. ACA primarily regulated BA and salt transport, as well as the signaling pathway associated with bile secretion. ACA pretreatment induced alterations in the liver BA pool, reducing the excessive accumulation of BAs and facilitating the restoration of BA homeostasis. ACA also downregulated the expression of hepatic BA synthase Cyp8b1, while enhancing the expression of hepatic and renal efflux transporters.
JOURNAL OF APPLIED TOXICOLOGY
(2023)
Article
Pharmacology & Pharmacy
Taleah Farasyn, Sonia Pahwa, Chao Xu, Wei Yue
Summary: This study demonstrates that pre-incubation with OATP1B inhibitors potentiates inhibitory effects in physiologically relevant primary human hepatocytes, supporting the rationale of the current US FDA draft guidance. IC50 values after inhibitor-preincubation in transporter-expressing cell lines may be used for DDI prediction for the purpose of mitigating false-negative OATP-mediated DDI prediction.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2021)
Article
Toxicology
Miao Yan, Lin Guo, Jiating Ma, Yan Yang, Tingli Tang, Bikui Zhang, Wei Zhou, Wei Zou, Zhenyan Hou, Hongmei Gu, Hui Gong
Summary: This study evaluated the hepatoprotective effects of liquiritin (LQ) in cholestatic mice. The results showed that LQ can attenuate cholestatic liver injury by regulating the expression of Sirt1/FXR/Nrf2 and bile acid transporters. Additionally, LQ had a global regulatory effect on hepatic miRNA expression.
JOURNAL OF APPLIED TOXICOLOGY
(2023)
Article
Plant Sciences
Mengge Shi, Jie Tang, Tong Zhang, Han Han
Summary: Swertiamarin can alleviate ANIT-induced cholestasis by activating the farnesoid X receptor and bile acid excretion pathway.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Marlies Oorts, Pieter Van Brantegem, Neel Deferm, Sagnik Chatterjee, Erwin Dreesen, Axelle Cooreman, Mathieu Vinken, Lysiane Richert, Pieter Annaert
Summary: Bosentan was evaluated at therapeutically relevant concentrations (2.5-25 μM) in sandwich-cultured human hepatocytes. It altered bile salt disposition and inhibited canalicular secretion of glycochenodeoxycholic acid (GCDCA). Within 24 hours, bosentan caused a shift from canalicular to sinusoidal efflux of GCDCA. These results also indicated reduced GCDCA formation. This study confirmed a direct effect of bosentan on chenodeoxycholic acid conjugation with glycine in liver S9 fraction.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2021)
Article
Plant Sciences
FanCheng Meng, Wei Zong, XiaoDong Wei, YunYi Tao, GuoWei Wang, ZhiHua Liao, Min Chen
Summary: This study aimed to investigate the anti-cholestasis effect of Dolomiaea souliei and its potential mechanism against acute intrahepatic cholestasis induced by ANIT. The results demonstrated that D. souliei could exert anti-cholestasis effect by activating FXR-SHP axis, inhibiting bile acid synthesis, increasing bile secretion, and alleviating inflammatory response. Costunolide may be the main active component responsible for these effects, providing a potential therapeutic mechanism for D. souliei as an anti-cholestasis medicine in cholestatic liver diseases.
Article
Gastroenterology & Hepatology
Xinzhu Liu, Jiaxuan Wang, Maogang Li, Jiannan Qiu, Xingying Li, Li Qi, Jia Liu, Ping Liu, Guoxiang Xie, Xiaoning Wang
Summary: FXR plays a key role in both BA and FA metabolism in NAFLD combined with cholestasis, suggesting it may be a potential target for the treatment of disorders in BA and FA metabolism in this condition.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Yue Zu, Jinyu Yang, Chengliang Zhang, Dong Liu
Summary: Excessive estrogens can lead to intrahepatic cholestasis, resulting in liver injury and adverse pregnancy outcomes. The main pathogenic mechanisms include abnormalities in BA synthetic or metabolic enzymes and cell membrane fluidity.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Chuanrui Ma, Jiaqing Xiang, Guixiao Huang, Yaxi Zhao, Xinyu Wang, Han Wu, Kewei Jiang, Zhen Liang, Lin Kang, Guangyan Yang, Shu Yang
Summary: The study found that PTE can alleviate DDC or ANIT-induced cholestasis by activating SIRT1, inhibiting macrophage infiltration and activation in mouse liver, and improving hepatic bile metabolism through the SIRT1-FXR signaling pathway. Compared with UDCA, PTE is more effective in improving cholestatic liver injury.
FRONTIERS IN PHARMACOLOGY
(2021)